Guillaume Fond1, Laurent Boyer2, Mohamed Boucekine2, Latif A Aden2, Franck Schürhoff3, Arnaud Tessier4, Meja Andrianarisoa3, Fabrice Berna5, Lore Brunel3, Delphine Capdevielle6, Isabelle Chereau7, Jasmina Mallet8, Hélène Denizot7, Jean Michel Dorey9, Caroline Dubertret8, Julien Dubreucq10, Catherine Faget11, Franck Gabayet10, Romain Rey9, Raphaelle Richieri11, Christine Passerieux12, Aurélie Schandrin6, Mathieu Urbach12, Pierre Vidailhet5, Pierre Michel Llorca7, David Misdrahi13. 1. Fondation FondaMental, Créteil, France; Pôle de Psychiatrie et d'addictologie des Hôpitaux Universitaires H Mondor, INSERM U955, Eq 15 Psychiatrie Génétique et psychopathologie, DHU Pe-PSY, Université Paris Est-Créteil, Créteil, France; Clinique Jeanne d'Arc, Hôpital Privé Parisien, F-94160 Saint-Mandé, France. Electronic address: guillaume.fond@gmail.com. 2. Fondation FondaMental, Créteil, France; Aix-Marseille University, EA 3279 - Public Health, Chronic Diseases and Quality of Life - Research Unit, France. 3. Fondation FondaMental, Créteil, France; Pôle de Psychiatrie et d'addictologie des Hôpitaux Universitaires H Mondor, INSERM U955, Eq 15 Psychiatrie Génétique et psychopathologie, DHU Pe-PSY, Université Paris Est-Créteil, Créteil, France. 4. Centre Hospitalier Charles Perrens, Université de Bordeaux, CNRS UMR 5287-INCIA, F-33076 Bordeaux, France. 5. Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France. 6. Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1, INSERM 1061, Montpellier, France. 7. Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de Médecine, Université d'Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France. 8. Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm U894, Université Paris Diderot, Sorbonne Paris Cité, Faculté de médecine, France. 9. Fondation FondaMental, Créteil, France; Université Claude Bernard Lyon 1/Centre Hospitalier Le Vinatier Pole Est BP 300 39, 95 bd Pinel, 69678 BRON Cedex, France. 10. Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble, France. 11. Fondation FondaMental, Créteil, France; Assistance Publique des Hôpitaux de Marseille (AP-HM), pôle universitaire de psychiatrie, Marseille, France. 12. Fondation FondaMental, Créteil, France; Service de psychiatrie d'adulte, Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en Yvelines, Versailles, France. 13. Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens, Université de Bordeaux, CNRS UMR 5287-INCIA, F-33076 Bordeaux, France.
Abstract
OBJECTIVE: The Medication Adherence Rating Scale (MARS) is one of the most widely used measurements of adherence in schizophrenia (SZ). However, the data available regarding its psychometric properties are scarce. The aim of this study was to provide new data regarding the psychometric properties of the MARS in a multicenter community-dwelling sample of SZ patients. METHODS: This study was conducted in the French National network of the 10 FondaMental Expert Centers for SZ. The MARS was tested for construct validity, reliability, external validity and acceptability. In addition, data pertaining to sociodemographic information, clinical characteristics using the Positive and Negative Syndrome Scale (PANSS), the Scale to Assess Unawareness in Mental Disorder (SUMD), the Calgary Depression Scale for Schizophrenia (CDRS) and therapeutic adherence using the Brief Adherence Rating Scale (BARS) were collected. RESULTS: Three hundred and nineteen patients were included. The 3-factor structure of the MARS was confirmed using confirmatory factor analysis: RMSEA=0.05, CFI=0.95, and WRMR=0.88. The unidimensionality of each factor was supported by the satisfactory INFIT statistics. Item internal consistencies were all higher than 0.15 and the Kuder-Richardson were close to 0.6, except for factor 2, which was close to 0.5. Significant associations with BARS, PANSS, CDRS showed satisfactory external validity. The acceptability was excellent as all patients complete the MARS, without missing values. CONCLUSION: The MARS is a short self-administered instrument with acceptable psychometric properties that yields important information about adherence to pharmacological treatment. Some improvements might be considered to enhance its validity and reliability.
OBJECTIVE: The Medication Adherence Rating Scale (MARS) is one of the most widely used measurements of adherence in schizophrenia (SZ). However, the data available regarding its psychometric properties are scarce. The aim of this study was to provide new data regarding the psychometric properties of the MARS in a multicenter community-dwelling sample of SZ patients. METHODS: This study was conducted in the French National network of the 10 FondaMental Expert Centers for SZ. The MARS was tested for construct validity, reliability, external validity and acceptability. In addition, data pertaining to sociodemographic information, clinical characteristics using the Positive and Negative Syndrome Scale (PANSS), the Scale to Assess Unawareness in Mental Disorder (SUMD), the Calgary Depression Scale for Schizophrenia (CDRS) and therapeutic adherence using the Brief Adherence Rating Scale (BARS) were collected. RESULTS: Three hundred and nineteen patients were included. The 3-factor structure of the MARS was confirmed using confirmatory factor analysis: RMSEA=0.05, CFI=0.95, and WRMR=0.88. The unidimensionality of each factor was supported by the satisfactory INFIT statistics. Item internal consistencies were all higher than 0.15 and the Kuder-Richardson were close to 0.6, except for factor 2, which was close to 0.5. Significant associations with BARS, PANSS, CDRS showed satisfactory external validity. The acceptability was excellent as all patients complete the MARS, without missing values. CONCLUSION: The MARS is a short self-administered instrument with acceptable psychometric properties that yields important information about adherence to pharmacological treatment. Some improvements might be considered to enhance its validity and reliability.
Authors: A Tinland; K Zemmour; P Auquier; M Boucekine; V Girard; S Loubière; G Fond; Laurent Boyer Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2017-06-27 Impact factor: 4.328
Authors: A Garosi; P L Sunhary de Verville; D Etchecopar-Etchart; R Richieri; O Godin; F Schürhoff; F Berna; B Aouizerate; D Capdevielle; I Chereau; J Clauss-Kobayashi; J M Dorey; C Dubertret; N Coulon; S Leignier; J Mallet; D Misdrahi; C Passerieux; R Rey; A Szoke; M Urbach; M Leboyer; P M Llorca; C Lançon; L Boyer; G Fond Journal: Eur Arch Psychiatry Clin Neurosci Date: 2022-07-19 Impact factor: 5.760
Authors: Stefano Barlati; Alberto Stefana; Francesco Bartoli; Giorgio Bianconi; Viola Bulgari; Valentina Candini; Giuseppe Carrà; Cesare Cavalera; Massimo Clerici; Marta Cricelli; Maria Teresa Ferla; Clarissa Ferrari; Laura Iozzino; Ambra Macis; Antonio Vita; Giovanni de Girolamo Journal: PLoS One Date: 2019-04-16 Impact factor: 3.240
Authors: Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong Journal: J Med Internet Res Date: 2020-10-08 Impact factor: 5.428